John N. Brewin

John N. Brewin

Auto-generated profile, based on publicly available information

John N. Brewin

Department of Haematological Medicine King's College Hospital London UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Blood Reviews
Verified
Journal Article
Open access
DRDavid Rees
David Rees
VBValentine A.M. Brousse
Valentine A.M. Brousse
JBJohn N. Brewin
John N. Brewin
Sickle cell disease is a very variable condition, with outcomes ranging from death in childhood to living relatively symptom free into the 8th decade. Much of this variability is unexplained. The co-inheritance of α thalassaemia and factors determining HbF levels significantly modify the phenotype, but few other significant genetic variants have been identified, despite extensive studies. Environmental factors are undoubtedly important, with socio-economics and access to basic medical care explaining the huge differences in outcomes between many low- and high-income countries. Exposure to cold and windy weather seems to precipitate acute complications in many people, although these effects are unpredictable and vary with geography. Many studies have tried to identify prognostic factors which can be used to predict outcomes, particularly when applied in infancy. Overall, low haemoglobin, low haemoglobin F percentage and high reticulocytes in childhood are associated with worse outcomes, although again these effects are fairly weak and inconsistent.

13 August 2019 in Frontiers in Physiology
Verified
Journal Article
Open access
HBHalima Al Balushi
Halima Al Balushi
AHAnke Hannemann
Anke Hannemann
DRDavid Rees
David Rees
JBJohn Brewin
John Brewin
JGJohn Stanley Gibson
John Stanley Gibson
Oxidative damage to red blood cells (RBCs) may contribute to pathogenesis of sickle cell anemia. Reducing the deleterious effects of oxidants by exposing RBCs to a number of antioxidants has been shown to have protective effects against lipid and protein peroxidation. We hypothesize that antioxidants may also have beneficial effects on the abnormal membrane permeability of sickle cells. Increased cation permeability of these cells encourages HbS polymerization by causing RBC dehydration and also leads to externalization of the prothrombotic aminophospholipid phosphatidylserine (PS). Three antioxidants with different mechanisms of action were investigated – dithiothreitol, N-acetylcysteine, and quercetin. All three were found to inhibit the main cation pathways responsible for dehydration – the deoxygenation-induced cation conductance (or Psickle), the Ca2+-activated K+ channel (or Gardos channel), and the K+-Cl− cotransporter. They also reduced Ca2+-induced PS exposure and hemolysis. Findings provide evidence for additional beneficial actions of antioxidants in maintenance of rheology and reducing vascular adhesion and further inform the rationale for their clinical use.

20 September 2018 in Haematologica
Verified
Journal Article
Closed access
PDF file
HRHelen Rooks
Helen Rooks
JBJohn Brewin
John Brewin
KGKate Gardner
Kate Gardner
SCSubarna Chakravorty
Subarna Chakravorty
SMStephan Menzel
Stephan Menzel
DRDavid Rees
David Rees

25 June 2018 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
AHAnke Hannemann
Anke Hannemann
DRDavid Rees
David Rees
JBJohn N. Brewin
John N. Brewin
ANAndreas Noe
Andreas Noe
BLBen Low
Ben Low
JGJohn S. Gibson
John S. Gibson
Summary: Phosphatidylserine (PS) exposure increases as red cells age, and is an important signal for the removal of senescent cells from the circulation. PS exposure is elevated in red cells from sickle cell anaemia (SCA) patients and is thought to enhance haemolysis and vaso‐occlusion. Although precise conditions leading to its externalisation are unclear, high intracellular Ca2+ has been implicated. Red cells from SCA patients are also exposed to an increased oxidative challenge, and we postulated that this stimulates PS exposure, through increased Ca2+ levels. We tested four different ways of generating oxidative stress: hypoxanthine and xanthine oxidase, phenazine methosulphate, nitrite and tert‐butyl hydroperoxide, together with thiol modification with N‐ethylmaleimide (NEM), dithiothreitol and hypochlorous acid (HOCl), in red cells permeabilised to Ca2+ using bromo‐A23187. Unexpectedly, our findings showed that the four oxidants significantly reduced Ca2+‐induced PS exposure (by 40–60%) with no appreciable effect on Ca2+ affinity. By contrast, NEM markedly increased PS exposure (by about 400%) and slightly but significantly increased the affinity for Ca2+. Dithiothreitol modestly reduced PS exposure (by 25%) and HOCl had no effect. These findings emphasise the importance of thiol modification for PS exposure in sickle cells but suggest that increased oxidant stress alone is not important.

10 October 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
JBJohn Brewin
John Brewin
GHGillian Horne
Gillian Horne
TCTimothy Chevassut
Timothy Chevassut
To the Editor: In reviewing the analysis of the genomic and epigenomic landscapes of de novo acute myeloid leukemia (AML) by the Cancer Genome Atlas Research Network (May 30 issue),1 we were struck by an apparent discrepancy in the reported clonal architecture of the AML samples as compared with that reported by Ding et al.2 (an average of one to two distinct clones identified vs. four or more). This discrepancy may reflect the limited depth of the sequencing analysis performed in the more recent study.1 More important, the authors do not reveal which mutations occur in the founding clone, as . . .

15 March 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
STSanjay Tewari
Sanjay Tewari
GRGeorge Renney
George Renney
JBJohn Brewin
John Brewin
KGKate Gardner
Kate Gardner
FKFenella Kirkham
Fenella Kirkham
DRDavid Rees
David Rees
Silent cerebral infarction is the most common neurological abnormality in children with sickle cell anemia, affecting 30-40% of 14 year olds. There are no known biomarkers to identify children with silent cerebral infarcts, and the pathological basis is also unknown. We used an unbiased proteomic discovery approach to identify plasma proteins differing in concentration between children with and without silent cerebral infarcts. Clinical parameters and plasma samples were analysed from 51 children (mean age 11.8 years, range 6-18) with sickle cell anemia (HbSS). A total of 19 children had silent cerebral infarcts and 32 normal MRI; the children with silent infarcts had lower HbF levels (8.6 vs. 16.1%, P=0.049) and higher systolic blood pressures (115 vs. 108.6, P=0.027). Plasma proteomic analysis showed 13 proteins increased more than 1.3 fold in the SCI patients, including proteins involved in hypercoagulability (α2-antiplasmin, fibrinogen−γ chain, thrombospondin-4), inflammation (α2-macroglobulin, complement C1s and C3), and atherosclerosis (apolipoprotein B-100). Higher levels of gelsolin and retinol-binding protein 4 were also found in the population with silent infarcts, both of which have been linked to stroke. We investigated the genetic basis of these differences by studying 359 adults with sickle cell disease (199 with silent cerebral infarcts, 160 normal MRIs), who had previously undergone a genome-wide genotyping array. None of the genes coding for the differentially expressed proteins were significantly associated with silent infarction. Our study suggests that silent cerebral infarcts in sickle cell anemia may be associated with higher systolic blood pressure, lower HbF levels, hypercoagulability, inflammation and atherosclerotic lipoproteins.